News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Hikma Pharmaceuticals Says Plans London IPO
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Oct 17 (Reuters) - Generic drug company Hikma Pharmaceuticals said on Monday it planned to float on the London Stock Exchange with a price range of 265 to 330 pence, the middle of which values it at about 500 million pounds ($874.9 million).
Twitter
LinkedIn
Facebook
Email
Print
IPO
Europe
Hikma Pharmaceuticals
MORE ON THIS TOPIC
Deals
An Insmed takeout by Sanofi would be ‘clear strategic fit’ in respiratory space
November 20, 2026
·
2 min read
·
Heather McKenzie
Cancer
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
November 20, 2026
·
3 min read
·
Gabrielle Masson
Licensing
AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal
November 19, 2026
·
1 min read
·
Annalee Armstrong
Job Trends
Ramping up: 3 biotechs growing their workforce after series C raises
November 19, 2026
·
4 min read
·
Angela Gabriel